Beclin-1 and LC3 are overexpressed in breast cancers and are associated with poor survival in TNBC patients, suggesting that targeting FOXM1 may suppress the tumor-promoting autophagic process [69]. This evidence concerns the gene FOXM1 and breast carcinoma.